Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor Simeprevir and frequently used concomitant medications.
| Author | |
|---|---|
| Abstract |
:
Direct-acting antivirals (DAAs) for the treatment of hepatitis C (HCV) can be associated with drug-drug interactions (DDIs) with concomitant medications. The practical clinical implications of such DDIs are poorly understood. We assessed the clinical impact of possible pharmacokinetic (PK) interactions between simeprevir and frequently prescribed concomitant medications. |
| Year of Publication |
:
2018
|
| Journal |
:
British journal of clinical pharmacology
|
| Date Published |
:
2018
|
| ISSN Number |
:
0306-5251
|
| URL |
:
http://dx.doi.org/10.1111/bcp.13519
|
| DOI |
:
10.1111/bcp.13519
|
| Short Title |
:
Br J Clin Pharmacol
|
| Download citation |
